RxDoctor Payments Data

Barry Leader, MD

Ophthalmology · New Orleans, LANPI 1952341554

Payments from drug & device makers

$5,276in general payments, 2019–2025

Across 88 payments — averaging $59.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
  • AbbVie$673
  • Alcon$325
  • Johnson & Johnson Surgical Vision, Inc.$233
  • Carl Zeiss Meditec USA, Inc.$196
  • Bausch & Lomb Americas Inc.$178
  • plus $780 from 15 others

What the payments were for

  • Speaking & faculty fees$2,60049%
  • Travel & lodging$701%
  • Food & beverage$2,60649%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,276 in reported general payments places this provider in the 75th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$157,312
Medicare patients
811
Services billed
1,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost204$92,515
RocklatanNetarsudil Mesylat/Latanoprost87$37,223
RestasisCyclosporine34$30,932
VyzultaLatanoprostene Bunod42$16,609
Latanoprost1,391$15,117
XiidraLifitegrast14$13,362
CombiganBrimonidine Tartrate/Timolol42$12,041
SimbrinzaBrinzolamide/Brimonidine Tart57$11,662
Travoprost77$10,363
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol78$8,799
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat798$7,852
RhopressaNetarsudil Mesylate17$6,361
Brimonidine Tartrate89$3,841
Prednisolone Acetate85$3,676
Tobramycin-DexamethasoneTobramycin/Dexamethasone62$3,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$673$135,487280 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$147$43,584104 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$178$29,97156 claims
AlconSimbrinza$325$11,66257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →